CAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of James C. Mullen as Chairman of the Board of Directors, effective immediately.
Mr. Mullen has more than 30 years of experience building leading biotechnology and pharmaceutical organizations on a global scale. Previously, Mr. Mullen served as Chief Executive Officer of Patheon N.V., a leading global provider of pharmaceutical development and manufacturing services, until its acquisition by Thermo Fisher Scientific, Inc. in August 2017. Before joining Patheon, Mr. Mullen served as Chief Executive Officer and President at Biogen, Inc., one of the world's largest biotechnology companies. Prior to being named Chief Executive Officer, Mr. Mullen held various operating positions at Biogen, including Chief Operating Officer, Vice President, International, and Vice President, Operations. Before joining Biogen, he held several manufacturing and engineering positions at SmithKline Beecham (now GlaxoSmithKline plc). Mr. Mullen also serves on the Board of Directors of Insulet Corporation and as Chairman of Board of Directors at Vicarius Pharma AG. He previously served on the Board of Directors of Patheon, Biogen, and PerkinElmer, Inc. He was also Chairman of the Board of Directors of the Biotechnology Innovation Organization.
“Jim is a renowned leader in the biotechnology industry with deep experience building global companies and guiding corporate strategy, and I am very pleased to welcome him as Chairman of the Board,” said Katrine Bosley, President and Chief Executive Officer, Editas Medicine. “Jim’s extensive experience in driving excellence across R&D, commercialization, manufacturing, business development, and capital formation will be invaluable as we continue to build a genomic medicine leader and develop medicines for patients in the years to come.”
“Editas Medicine is at the vanguard of genomic medicine, and I am delighted to join the Company’s Board of Directors as Chairman,” said Mr. Mullen. “I look forward to working with the Board and management team to help guide the Company towards achieving its mission and executing against the Company’s EM22 long-range goals.”
Mr. Mullen holds a Bachelor of Science in Chemical Engineering from Rensselaer Polytechnic Institute and a Master of Business Administration from Villanova University.
In addition, the Company announced that Alexis Borisy and John Mendlein, Ph.D., stepped down from the Board. Mr. Borisy, a Partner with Third Rock Ventures and a co-founder of Editas Medicine, joined the Board in 2013. Dr. Mendlein, who recently joined Moderna Therapeutics, Inc. as President, Corporate and Product Strategy, joined the Board in 2016.
“We are deeply appreciative of the many contributions Alexis and John made to Editas Medicine, both in the initial formation of the company and in our transition from a private to public company. We wish them well with their professional responsibilities,” said Ms. Bosley.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Source: Editas Medicine, Inc.